DaVita Inc. (DVA)

NYSE: DVA · USD

$184

+2.47 (+1.4%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-09-20

Our latest published analysis: DVA rated Strong Buy

DaVita Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$386 / share

Potential value

$491 / share

Upside to FV

+110.2%

from $184

Moat

7/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$11.7B
Revenue (ttm)	14B
Net income (ttm)	847.5M
EPS (ttm)	$12.1
Shares out	63.8M
P/E (trailing)	15.2x
P/E (forward)	10.0x
Volume	344,186
Beta	0.80

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 14B
Net income (ttm): 847.5M
EPS (ttm): $12.1
P/E (trailing): 15.2x
P/E (forward): 10.0x
Market cap: $11.7B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$11.62B	$11.61B	$12.14B	$12.82B	$13.64B	+4.1%
Gross profit	$3.65B	$3.40B	$3.82B	$4.22B	$3.68B	+0.3%
Operating income	$1.80B	$1.34B	$1.60B	$2.09B	$2.04B	+3.3%
Net income	$978.5M	$560.4M	$691.5M	$936.3M	$746.8M	-6.5%
EPS (diluted)	$8.90	$5.85	$7.42	$10.73	$9.84	+2.5%
EBITDA	$2.48B	$2.06B	$2.32B	$2.72B	$2.64B	+1.6%
R&D	—	—	—	—	—	—
SG&A	$1.20B	$1.36B	$1.47B	$1.54B	$1.67B	+8.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base60%

Price target

$386.49

+110.2% from spot

The base path expects steady outpatient dialysis treatment volume expansion, stable commercial reimbursement agreements, and disciplined center cost management. Continued free cash flow generation enables ongoing share repurchases that compound per-share earnings, supporting a target of $386.49 with a probability of 60.0% and an expected return of 110.2% relative to $183.86.

Treatment volume expands at demographic rates
Operating margins remain near normalized levels
Free cash flow continues funding regular share buybacks

Bull20%

Price target

$490.58

+166.8% from spot

The bull path assumes accelerated expansion in integrated kidney care programs, favorable commercial payer renewals, and enhanced clinical staffing productivity. Accelerated share repurchases compound diluted earnings per share, driving the target to $490.58 with an estimated probability of 20.0% and a return of 166.8% over $183.86.

Integrated kidney care contracts accelerate revenue growth
Commercial reimbursement rates expand ahead of clinical inflation
Accelerated share repurchases shrink share count faster than baseline

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($386.49). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
6.3%	$521	$591	$699	$891	$1,398
7.3%	$408	$444	$492	$558	$660
8.3%	$338	$359	$386	$420	$465
9.3%	$289	$303	$320	$340	$365
10.3%	$253	$263	$274	$287	$303

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E10

P25 n/aP50 n/aP75 n/a

Trailing P/E15.6

P25 n/aP50 n/aP75 n/a

ROE88.5

P25 n/aP50 n/aP75 n/a

ROIC12.3

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DVA indicators

Market & fundamental data

Available fields

276

Groups with data

Currency

USD

Showing 276 of 276 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000927066
Company name	DaVita Inc.
Country	United States
Country code	US
CUSIP number	23918K108
Earnings date	2026-10-29
Earnings time	amc
Employees	78,000
Employees change	2,000
Employees growth	2.63%
Enterprise value	$24.5B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1994
In index	SP500
Industry	Medical Care Facilities
IPO date	1995-10-31
Is primary listing	Yes
Is SPAC	No
ISIN number	US23918K1088
Last 10-K release date	2026-02-11
Last earnings date	2026-08-04
Last refreshed	2026-10-28
Last stock split date	2013-09-09
Last stock split type	Forward
Market cap	$11.7B
Market cap category	Large-Cap
Next earnings date	2026-10-29
Options	Yes
Price	$184.17
Price currency	USD
Sector	Healthcare
SIC code	8090
Stock price date	2026-10-28
Symbol	DVA
U.S. state	Colorado
Website	https://www.davita.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	14.39x
Average P/E ratio (10Y)	18.53x
Average P/E ratio (3Y)	13.93x
Average P/E ratio (5Y)	13.48x
Earnings yield	6.57%
EV/Earnings	28.86x
EV/EBIT	11.56x
EV/EBITDA	8.65x
EV/FCF	15.19x
EV/Sales	1.75x
FCF / EV yield	6.58%
FCF yield	13.71%
Forward EV/Sales	1.72x
Forward P/E	11.73x
Forward P/S	0.82x
Industry forward P/E	14.81x
Industry P/E	18.21x
Lynch fair value	$60.54
Lynch upside	-67.12%
P/(FCF - SBC) ratio	7.94x
P/(OCF - SBC) ratio	5.7x
P/B ratio	10.88x
P/E ratio	15.21x
P/FCF ratio	7.29x
P/OCF ratio	5.35x
P/S ratio	0.84x
PEG ratio	0.44x
Price/EBITDA ratio	4.15x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	15.11%
EBITDA margin	20.17%
Effective tax rate	20.66%
FCF margin	11.49%
Gross margin	32.36%
Operating margin	15.11%
Pretax margin	10.48%
Profit margin	6.05%
Profit per employee	$10,865
Profitable quarters	30
Profitable years	26
Revenue per employee	$179,611
ROA	7.51%
ROA (5Y)	6.34%
ROCE	14.25%
ROE	88.48%
ROE (5Y)	46.91%
ROIC	12.26%
ROIC (5Y)	10.25%
SBC / revenue	0.94%
Tax / revenue	2.16%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	18.73%
EPS growth (Q)	55.81%
EPS growth (QoQ)	40.07%
EPS growth 10Y	21.55%
EPS growth 3Y	33.8%
EPS growth 5Y	10.25%
EPS growth quarters	3
EPS growth years	0
FCF growth	24.96%
FCF growth (Q)	57.65%
FCF growth (QoQ)	46.36%
FCF growth 3Y	5.87%
FCF growth 5Y	7.44%
Gross profit growth	5.87%
Gross profit growth (Q)	3.94%
Gross profit growth 3Y	9.53%
Gross profit growth 5Y	4.53%
Net income growth	1.34%
Net income growth (Q)	33.14%
Net income growth (QoQ)	34.36%
Net income growth 3Y	21.91%
Net income growth 5Y	-0.38%
Net income growth quarters	2
Net income growth years	0
OCF growth	17.77%
OCF growth (Q)	51.15%
OCF growth (QoQ)	52.75%
OCF growth 10Y	0.62%
OCF growth 3Y	3.7%
OCF growth 5Y	4.01%
Operating income growth	7.12%
Operating income growth (Q)	7.6%
Operating income growth 3Y	18.18%
Operating income growth 5Y	4.08%
Revenue growth	6.45%
Revenue growth (Q)	5.17%
Revenue growth (QoQ)	4.06%
Revenue growth 10Y	-0.24%
Revenue growth 3Y	6.07%
Revenue growth 5Y	3.91%
Revenue growth quarters	14
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-583.4M
Depreciation and amortization	$709.8M
EBIT	$2.1B
EBITDA	$2.8B
EPS	$12.11
FCF per share	$25.24
Financing cash flow	$-1.5B
Free cash flow	$1.6B
Free cash flow minus SBC	$1.5B
Gross profit	$4.5B
Income taxes	$303.3M
Investing cash flow	$-759M
Net borrowing	$510.9M
Net cash flow	$-45.1M
Net income	$847.5M
Operating cash flow minus SBC	$2.1B
Operating income	$2.1B
Revenue	$14B
Stock-based compensation	$131.6M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.64
Book value per share	$-11.96
Debt / EBITDA	3.79
Debt / equity	12.42
Debt / FCF	8.33
Goodwill	$7.6B
Interest coverage	3.65
Long-term assets	$13.5B
Long-term liabilities	$13.8B
Net cash (debt)	$-12.7B
Net cash / market cap	-108.31%
Net debt / EBITDA	4.5
Net debt / equity	11.78
Net debt / FCF	7.9
Piotroski F-Score	6
Property, plant and equipment	$5.2B
Shareholders' equity	$1.1B
Tangible book value	$-8.6B
Tangible book value per share	$-134.23
Total assets	$17.7B
Total cash	$688.9M
Total debt	$13.4B
Total liabilities	$16.6B
WACC	5.86%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.8
Current assets	$4.2B
Current liabilities	$2.9B
Current ratio	1.47
Inventory turnover	63.63
Net working capital	$1.2B
Quick ratio	1.33
Working capital	$1.3B
Working capital turnover	11.26

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	14.73%
Dividend yield	0%
Shareholder yield	14.73%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	229.29%
10Y return CAGR	12.66%
10Y total return	229.29%
150-day SMA	$189.08
15Y price change	411.44%
15Y return CAGR	11.49%
15Y total return	411.44%
1D price change	1.36%
1M price change	3.19%
1M total return	3.19%
1W price change	4.16%
1W total return	4.16%
1Y price change	42.16%
1Y return CAGR	42.2%
1Y total return	42.16%
20-day SMA	$181.35
200-day SMA	$176.15
20Y price change	552.39%
20Y return CAGR	9.83%
20Y total return	552.39%
3M price change	-22.06%
3M total return	-22.06%
3Y price change	139.9%
3Y return CAGR	33.86%
3Y total return	139.9%
50-day SMA	$180.84
50-day SMA vs 200-day SMA	50over200
52-week high	$247.49
52-week high date	2026-08-03
52-week low	$101.00
52-week low date	2026-01-14
5Y price change	66.04%
5Y return CAGR	10.68%
5Y total return	66.04%
6M price change	22.74%
6M total return	22.74%
All-time high	$247.49
All-time high date	2026-08-03
All-time low	$0.69
All-time low date	2000-03-02
Average true range (ATR)	$5.55
Average volume	631.6K
Beta (1Y)	-0.42
Beta (2Y)	0.22
Beta (5Y)	0.8
Change from 52-week high	-25.58%
Change from 52-week low	82.35%
Change from all-time high	-25.58%
Change from all-time low	26,688.36%
Change from open	0.69%
Day's gap	0.67%
Dollar volume	$63.4M
High price	$184.27
Low price	$182.54
Monthly RSI	56.75
Open price	$182.90
Position in 52-week range	94.22%
Premarket change	1.27%
Premarket close	$181.69
Premarket price	$183.99
Previous close	$181.69
Price vs 150-day SMA	-2.6%
Price vs 20-day SMA	1.55%
Price vs 200-day SMA	4.55%
Price vs 50-day SMA	1.84%
Relative volume	0.55
RSI	52.34
Sharpe ratio	0.9
Sharpe ratio (3Y)	0.84
Sharpe ratio (5Y)	0.34
Sortino ratio	1.68
Sortino ratio (3Y)	1.48
Sortino ratio (5Y)	0.61
Volume	344.2K
Weekly RSI	51.18
YTD price change	62.11%
YTD total return	62.11%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	33.9M
Float percentage	53.18%
Shares change (QoQ)	-4.04%
Shares change (YoY)	-14.73%
Shares held by insiders	1.75%
Shares held by institutions	47.94%
Shares outstanding	63.8M
Short % of float	15.18%
Short % of shares	8.07%
Short ratio	7.2 days

Deeper analysis on DVA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this DVA report

What is the latest published DVA stock rating?

DaVita Inc. is shown with Strong Buy in the latest published report, analyzed 2026-09-20. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full DVA analysis?

The full latest published report, analyzed 2026-09-20, lives at /stocks/DVA/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for DVA?

The latest published report analyzed 2026-09-20 gives DVA a fair value of USD 386 and a potential value of USD 491. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the DVA page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-20). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Strong BuyDVA · Fair value $386+110.2%

Read full analysis →

Category	Score	Reading
Valuation	9.5
Management	6.5
Balance Sheet	3.5
Profitability	7.0
Revenue Growth	6.0
Risk Assessment	4.0
Competitive Moat	7.0
Earnings Quality	9.0
Capital Efficiency	6.5

DaVita Inc. (DVA)

Our latest published analysis: DVA rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · DVA

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All DVA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DVA

Frequently asked questions

评级历史